LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

67.99 -0.9

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

67.76

Maxim

69.24

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	24.112 50.102
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+17.23% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	501M 8.2B
Deschiderea anterioară	68.89
Închiderea anterioară	67.99

Sentimentul știrilor

By Acuity

11%

89%

9 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 mai 2026, 21:33 UTC

Câștiguri

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mai 2026, 21:00 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mai 2026, 20:18 UTC

Câștiguri

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mai 2026, 21:29 UTC

Acțiuni populare

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mai 2026, 21:08 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mai 2026, 21:02 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mai 2026, 20:59 UTC

Achiziții, Fuziuni, Preluări

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mai 2026, 20:55 UTC

Câștiguri

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 mai 2026, 20:48 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mai 2026, 20:45 UTC

Câștiguri

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mai 2026, 20:34 UTC

Achiziții, Fuziuni, Preluări

Webster Financial Stockholders Approve Sale to Banco Santander

27 mai 2026, 20:32 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mai 2026, 20:30 UTC

Câștiguri

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mai 2026, 20:30 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mai 2026, 20:22 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:16 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mai 2026, 20:13 UTC

Câștiguri

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

17.23% sus

Prognoză pe 12 luni

Medie 80.48 USD 17.23%

Maxim 96 USD

Minim 66.41 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

9 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.